Advertisement

AAPS PharmSciTech

, 20:26 | Cite as

Lipid Nanoemulsions of Rebamipide: Formulation, Characterization, and In Vivo Evaluation of Pharmacokinetic and Pharmacodynamic Effects

  • Arjun Narala
  • Swathi Guda
  • Kishan VeerabrahmaEmail author
Research Article Theme: Lipid-Based Drug Delivery Strategies for Oral Drug Delivery
  • 27 Downloads
Part of the following topical collections:
  1. Theme: Lipid-Based Drug Delivery Strategies for Oral Drug Delivery

Abstract

Rebamipide has low oral bioavailability (10%) due to its low solubility and permeability. Lipid nanoemulsions (LNEs) were prepared in order to improve its oral bioavailability. Rebamipide-loaded lipid nanoemulsions were formulated by hot homogenization and ultrasonication method. Olive oil and egg lecithin in various concentrations as emulsifier were used in the preparation of LNEs. The lipid nanoemulsions were evaluated for various parameters. The globule size, polydispersity index (PDI), and zeta potential (ZP) of the formulations ranged from 230.3 ± 3.88 to 279.8 ± 5.76 nm, 0.204 ± 0.008 to 0.246 ± 0.029, and − 27.7 ± 2.05 to − 31.0 ± 1.87 mV, respectively. Entrapment efficiency and assay values ranged from 99.90 ± 0.006 to 99.92 ± 0.002% and 99.3 ± 0.808 to 99.6 ± 0.360, respectively. Physical stability test results revealed that the optimized LNEs were stable for 2 months at both room (25°C) and refrigerated temperature (4°C). The optimized LNE showed 4.32-fold improvement in the oral bioavailability in comparison to a marketed tablet suspension. In vivo anti ulcer activity of rebamipide LNE was studied by testing the prophylactic effect in preventing the mucosal damage in stomach region. The mucosa of stomach in animals was damaged by per oral administration of 80% alcohol. Maximum prophylactic antiulcer activity was observed by per oral delivery of rebamipide as LNE. Our results indicated that LNEs were a promising approach for the oral delivery of rebamipide for systemic effects along with local effects in protecting gastric region, which gets damaged during peptic ulcers.

KEY WORDS

rebamipide bioavailability lipid nanoemulsions antiulcer activity prophylactic 

Notes

Acknowledgements

The authors thank UCPSc, KU, Warangal for providing all the requirements to carry out research. Further, the authors thank Prof. Veerabhadra Rao, pathologist of M/s. VBR Diagnostics, for help in histopathological studies.

Compliance with Ethical Standards

Ethical Committee Approval

The animal protocol was approved by the IAEC (Protocol no. IAEC/4/UCPSC/KU/2017). The animal treatment in the study was according to CPCSEA guidelines.

Declaration

The authors declare that there is no conflict of interest.

References

  1. 1.
    Tung NT, Park CW, Oh TO, Kim JY, Ha JM, Rhee YS, et al. Formulation of solid dispersion of rebamipide evaluated in a rat model for improved bioavailability and efficacy. J Pharm Pharmacol. 2011;63(12):1539–47.CrossRefGoogle Scholar
  2. 2.
    Genta RM. The role of rebamipide in the management of inflammatory disease of the gastrointestinal tract. Aliment Pharmacol Ther. 2003;18(Suppl. 1):8–13.CrossRefGoogle Scholar
  3. 3.
    Kim KT, Lee J-Y, Park J-H, Cho H-J, Yoon I-S, Kim D-D. Capmul MCM/Solutol HS15-based microemulsion for enhanced oral bioavailability of rebamipide. J Nanosci Nanotechnol. 2017;17:2340–4.CrossRefGoogle Scholar
  4. 4.
    Pradhan R, Tran TH, Choi JY, Choi IS, Choi HG, Yong CS, et al. Development of a rebamipide solid dispersion system with improved dissolution and oral bioavailability. Arch Pharm Res. 2015;38:522–33.CrossRefGoogle Scholar
  5. 5.
    Guo Y, Wang Y, Xu L. Enhanced bioavailability of rebamipide nanocrystal tablets: formulation and in vitro/in vivo evaluation. Asian J Pharm Sci. 2015;10(3):223–9.CrossRefGoogle Scholar
  6. 6.
    Deitel M, Friedman KL, Cunnane S, Lea PJ, Chaiet A, Chong J, et al. Emulsion stability in a total nutrient admixture for total parenteral nutrition. J Am Coll Nutr. 1992;11:5–10.CrossRefGoogle Scholar
  7. 7.
    Gettings SD, Lordo RA, Feder PI, Hintze KL. A comparison of low volume, draize and in vitro eye irritation test data. II. Oil/water emulsions. Food Chem Toxicol. 1998;36:47–59.CrossRefGoogle Scholar
  8. 8.
    Mizushima Y. Lipid microspheres (lipid emulsions) as a drug carrier—an overview. Adv Drug Deliv Rev. 1996;20:113–5.CrossRefGoogle Scholar
  9. 9.
    Singh M, Ravin LJ. Parenteral emulsions as drug carrier systems. J Parenter Sci Technol. 1986;40:34–41.PubMedGoogle Scholar
  10. 10.
    Takino T, Konishi K, Takakura Y, Hashida M. Long circulating emulsion carrier systems for highly lipophilic drugs. Biol Pharm Bull. 1994;17:121–5.CrossRefGoogle Scholar
  11. 11.
    Floyd AG. Top ten considerations in the development of parenteral emulsions. Pharm Sci Technol Today. 1999;2:134–43.CrossRefGoogle Scholar
  12. 12.
    Devalapally H, Silchenko S, Zhou F, McDade J, Goloverda G, Owen A, et al. Evaluation of a nanoemulsion formulation strategy for oral bioavailability enhancement of danazol in rats and dogs. J Pharm Sci. 2013;102(10):3808–15.CrossRefGoogle Scholar
  13. 13.
    Patel Y, Poddar A, Sawant K. Formulation and characterization of cefuroxime Axetil nanoemulsion for improved bioavailability. J Pharm Bioallied Sci. 2012;4(Suppl 1):S4–5.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Zhao L, Wei Y, Huang Y, He B, Zhou Y, Fu J. Nanoemulsion improves the oral bioavailability of baicalin in rats: in vitro and in vivo evaluation. Int J Nanomedicine. 2013;8:3769–79.CrossRefGoogle Scholar
  15. 15.
    Sun L, Wan K, Hu X, Zhang Y, Yan Z, Feng J, et al. Functional nanoemulsion-hybrid lipid nanocarriers enhance the bioavailability and anti-cancer activity of lipophilic diferuloylmethane. Nanotechnology. 2016;27(8):085102.CrossRefGoogle Scholar
  16. 16.
    Varshika E, Prabhakar K, Kishan V. Preparation, characterization and in vivo pharmacodynamic evaluation of parenteral diclofenac submicron lipid emulsions. PDA J Pharm Sci Technol. 2009;63(2):380–9.PubMedGoogle Scholar
  17. 17.
    Afzal SM, Shareef MZ, Dinesh T, Kishan V. Folate-PEG-decorated docetaxel lipid nanoemulsion for improved antitumor activity. Nanomedicine (London). 2016;11(16):1–10.CrossRefGoogle Scholar
  18. 18.
    Muzammil Afzal S, Naidu VG, Harishankar N, Kishan V. Albumin anchored docetaxel lipid nanoemulsion for improved targeting efficiency—preparation, characterization, cytotoxic, antitumor and in vivo imaging studies. Drug Deliv. 2016;23(4):1355–63.PubMedGoogle Scholar
  19. 19.
    Syed MA, Veerabrahma K. Biodegradable preparation, characterization and in vitro evaluation of stealth docetaxel lipid nanoemulsions for efficient cytotoxicity. Int J Drug Deliv. 2013;5:188–95.Google Scholar
  20. 20.
    Geng T-Y, Xu C, Xu G-H. Albumin conjugated lipid nanoemulsion for site specific delivery of rapamycin at inflammatory site of spinal cord injury. Int J Clin Exp Med. 2016;9(11):21028–37.Google Scholar
  21. 21.
    Kandadi P, Syed MA, Goparaboina S, Veerabrahma K. Albumin coupled lipid nanoemulsions of diclofenac for targeted delivery to inflammation. Nanomed. 2012;8:1162–71.CrossRefGoogle Scholar
  22. 22.
    Kandadi P, Syed MA, Goparaboina S, Veerabrahma K. Brain specific delivery of pegylated indinavir submicron lipid emulsions. Eur J Pharm Sci. 2011;42:423–32.CrossRefGoogle Scholar
  23. 23.
    Prabhakar K, Afzal SM, Surender G, Kishan V. Tween 80 containing lipid nanoemulsions for delivery of indinavir to brain. Acta Pharm Sin B. 2013;3(5):345–53.CrossRefGoogle Scholar
  24. 24.
    Krishna G, Wood GC, Sheth BB. Improving emulsification efficacy of lecithin by formulation design. I: effect of adding a secondary surfactant. PDA J Pharm Sci Technol. 1998;52(6):331–6.PubMedGoogle Scholar
  25. 25.
    Liu Y, Yu X-M, Sun R-J, Pan X-L. Folate-functionalized lipid Nanoemulsion to deliver chemo-radiotherapeutics together for the effective treatment of nasopharyngeal carcinoma. AAPS PharmSciTech. 2017;18(4):1374–81.CrossRefGoogle Scholar
  26. 26.
    Madishetty S, Afzal SM, Prabhakar K, Kishan V. Cationic diclofenac lipid Nanoemulsion for improved oral bioavailability: preparation, characterization and in vivo evaluation. Int J Pharm Sci Nanotech. 2015;8(2):2874–80.Google Scholar
  27. 27.
    Li C-Y, Xu H-D, Zhao B-T, Chang H-I, Rhee H-I. Gastroprotective effect of cyanidin 3-glucoside on ethanol-induced gastric lesions in rats. Alcohol. 2008;42:683–7.CrossRefGoogle Scholar
  28. 28.
    Shotton E, Davis SS. A note on the stability of emulsion on high dilution. J Pharm Pharmacol. 1968;20:825–9.CrossRefGoogle Scholar
  29. 29.
    Porter CJH, Charman WN. Uptake of drugs into the intestinal lymphatics after oral administration. Adv Drug Deliv Rev. 1997;25:71–89.CrossRefGoogle Scholar
  30. 30.
    Singh Y, Meher JG, Raval K, Khan FA, Chaurasia M, Jain NK, et al. Nanoemulsion: concepts, development and applications in drug delivery. J Control Release. 2017;252:28–49.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2019

Authors and Affiliations

  1. 1.Department of Pharmaceutical Sciences, Laboratory of nanotechnology, University College of Pharmaceutical SciencesKakatiya UniversityWarangalIndia

Personalised recommendations